Matsumura Kazuki, Toyoda Yukitoshi, Matsumoto Shokei, Kawai Yoshiaki, Mori Takaaki, Omasa Kosei, Fukada Takuya, Yamada Masaki, Kazamaki Taku, Furugori Shintaro, Hiroe Nao, Senoo Satomi, Shimizu Masayuki, Funabiki Tomohiro, Yamazaki Motoyasu
Department of Emergency and Critical Care Medicine, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan.
Am J Case Rep. 2020 Aug 19;21:e926835. doi: 10.12659/AJCR.926835.
BACKGROUND Patients with coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 can rapidly progress to acute respiratory distress syndrome (ARDS). Because clinical diagnosis of ARDS includes several diseases, understanding the characteristics of COVID-19-related ARDS is necessary for precise treatment. We report 2 patients with ARDS due to COVID-19-associated pneumonia. CASE REPORT Case 1 involved a 72-year-old Japanese man who presented with respiratory distress and fever. Computed tomography (CT) revealed subpleural ground-glass opacities (GGOs) and consolidation. Six days after symptom onset, reverse transcription-polymerase chain reaction (RT-PCR) testing confirmed the diagnosis of COVID-19-associated pneumonia. He was intubated and received veno-venous extracorporeal membrane oxygenation (ECMO) 8 days after symptom onset. Follow-up CT revealed large diffuse areas with a crazy-paving pattern and consolidation, which indicated progression of COVID-19-associated pneumonia. Following treatment with antiviral medications and supportive measures, the patient was weaned off ECMO after 20 days. Case 2 involved a 70-year-old Asian man residing in Canada who presented with cough, malaise, nausea, vomiting, and fever. COVID-19-associated pneumonia was diagnosed based on a positive result from RT-PCR testing. The patient was then transferred to the intensive care unit and intubated 8 days after symptom onset. Follow-up CT showed that while the initial subpleural GGOs had improved, diffuse GGOs appeared, similar to those observed upon diffuse alveolar damage. He was administered systemic steroid therapy for ARDS and extubated after 6 days. CONCLUSIONS Because the pattern of symptom exacerbation in COVID-19-associated pneumonia cases seems inconsistent, individual treatment management, especially the CT-based treatment strategy, is crucial.
背景 由严重急性呼吸综合征冠状病毒2引起的2019冠状病毒病(COVID-19)患者可迅速进展为急性呼吸窘迫综合征(ARDS)。由于ARDS的临床诊断包括多种疾病,了解COVID-19相关ARDS的特征对于精确治疗很有必要。我们报告2例因COVID-19相关性肺炎导致ARDS的患者。病例报告 病例1为一名72岁的日本男性,出现呼吸窘迫和发热症状。计算机断层扫描(CT)显示胸膜下磨玻璃影(GGO)和实变。症状出现6天后,逆转录-聚合酶链反应(RT-PCR)检测确诊为COVID-19相关性肺炎。症状出现8天后,他接受了气管插管并接受了静脉-静脉体外膜肺氧合(ECMO)治疗。随访CT显示大片弥漫性区域呈铺路石样改变和实变,提示COVID-19相关性肺炎进展。经过抗病毒药物治疗和支持措施后,患者在20天后撤离ECMO。病例2为一名居住在加拿大的70岁亚洲男性,出现咳嗽、不适、恶心、呕吐和发热症状。基于RT-PCR检测阳性结果诊断为COVID-19相关性肺炎。患者随后被转入重症监护病房,并在症状出现8天后接受气管插管。随访CT显示,虽然最初的胸膜下GGO有所改善,但出现了弥漫性GGO,类似于弥漫性肺泡损伤时观察到的情况。他接受了针对ARDS的全身类固醇治疗,并在6天后拔管。结论 由于COVID-19相关性肺炎病例的症状加重模式似乎不一致,个体化治疗管理,尤其是基于CT的治疗策略至关重要。